Application

Title

Breast Cancer_PREDIX_LumB

Type

TissUUmaps App

URL

https://r0928505c.serve.scilifelab.se

Source code

Docker image

Created

17 Feb, 2026

Updated

18 Aug, 2026

Description

Needle biopsies from patients with ER+/HER2- invasive breast cancer who received 12 weeks of neoadjuvant treatment with the CDK4/6 inhibitor palbociclib in combination with endocrine therapy. Paired biopsies were collected at baseline (treatment-naive) and on-treatment (after 12 weeks). Objective response rates (ORR) were evaluated at 12 weeks, classifying patients into responders (R) and non-responders (NR). None of the patients achieved a pathological complete response at 12 weeks. Order of samples First row: Non-Responder 1 Baseline, Non-Responder 1 Visit, Non-Responder 2 Baseline, Non-Responder 2 Visit Second row: Non-Responder 3 Baseline, Non-Responder 3 Visit, Responder 1 Baseline, Responder 1 Visit Third row: Responder 2 Baseline, Responder 2 Visit, Responder 3 Baseline, Responder 3 Visit

Subjects & keywords